Toxicarioside A inhibits SGC-7901 proliferation, migration and invasion via NF-κB/bFGF signaling

World Journal of Gastroenterology

Volumn 18, Issue 14, 2012, Pages 1602-1609

  Guo, Jun Li ^a   Zheng, Shao Jiang ^a   Li, Yue Nan ^a   Jie, Wei ^b   Hao, Xin Bao ^a   Li, Tian Fa ^a   Xia, Li Ping ^a   Mei, Wen Li ^c   Huang, Feng Ying ^a   Kong, Yue Qiong ^a   He, Qi Yi ^a   Yang, Kun ^a   Tan, Guang Hong ^a   Dai, Hao Fu ^c  

^a HAINAN MEDICAL UNIVERSITY   (China)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

^c INSTITUTE OF TROPICAL BIOSCIENCE AND BIOTECHNOLOGY   (China)

Author keywords

Anti migration; Anti proliferation; Basic fibroblast growth factor; Gastric cancer; Nuclear factorkappa B; Toxicarioside A

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PLANT EXTRACT; TOXICARIOSIDE A; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER INVASION; CELL ASSAY; CELL MOTILITY; CELL VIABILITY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; PROTEIN EXPRESSION; PROTEIN INDUCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; WESTERN BLOTTING;

EID: 84859943470     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v18.i14.1602     Document Type: Article

References (40)

1. Shrestha T, Kopp B, Bisset NG. The Moraceae-based dart poisons of South America. Cardiac glycosides of Maquira and Naucleopsis species. J Ethnopharmacol 1992; 37: 129-143
2. Dong WH, Mei WL, Zhao YX, Zeng YB, Zuo WJ, Wang H, Li XN, Dai HF. Cytotoxic cardenolide glycosides from the seeds of Antiaris toxicaria. Planta Med 2011; 77: 1730-1734
3. Dong WH, Mei WL, Zhao YX, Zeng YB, Wang H, Dai HF. A new drimane sesquiterpenoid glycoside from the seeds of Antiaris toxicaria. J Asian Nat Prod Res 2011; 13: 561-565
4. Dai HF, Gan YJ, Que DM, Wu J, Wen ZC, Mei WL. Two new cytotoxic cardenolides from the latex of Antiaris toxicaria. J Asian Nat Prod Res 2009; 11: 832-837
5. Dai HF, Gan YJ, Que DM, Wu J, Wen ZC, Mei WL. A new cytotoxic 19-nor-cardenolide from the latex of Antiaris toxicaria. Molecules 2009; 14: 3694-3699
6. Shi LS, Liao YR, Su MJ, Lee AS, Kuo PC, Damu AG, Kuo SC, Sun HD, Lee KH, Wu TS. Cardiac glycosides from Antiaris toxicaria with potent cardiotonic activity. J Nat Prod 2010; 73: 1214-1222
7. Gheorghiade M, van Veldhuisen DJ, Colucci WS. Contemporary use of digoxin in the management of cardiovascular disorders. Circulation 2006; 113: 2556-2564
8. Hamad E, Mather PJ, Srinivasan S, Rubin S, Whellan DJ, Feldman AM. Pharmacologic therapy of chronic heart failure. Am J Cardiovasc Drugs 2007; 7: 235-248
9. Choedon T, Mathan G, Arya S, Kumar VL, Kumar V. Anticancer and cytotoxic properties of the latex of Calotropisprocera in a transgenic mouse model of hepatocellular carcinoma. World J Gastroenterol 2006; 12: 2517-2522
10. Yeh JY, Huang WJ, Kan SF, Wang PS. Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells. Prostate 2003; 54: 112-124
11. Frese S, Frese-Schaper M, Andres AC, Miescher D, Zumkehr B, Schmid RA. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5. Cancer Res 2006; 66: 5867-5874
12. Sreenivasan Y, Sarkar A, Manna SK. Oleandrin suppresses activation of nuclear transcription factor-kappa B and activator protein-1 and potentiates apoptosis induced by ceramide. Biochem Pharmacol 2003; 66: 2223-2239
13. McConkey DJ, Lin Y, Nutt LK, Ozel HZ, Newman RA. Cardiac glycosides stimulate Ca2+ increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinom cells. Cancer Res 2000; 60: 3807-3812
14. Lin J, Denmeade S, Carducci MA. HIF-1alpha and calcium signaling as targets for treatment of prostate cancer by cardiac glycosides. Curr Cancer Drug Targets 2009; 9: 881-887
15. Newman RA, Yang P, Pawlus AD, Block KI. Cardiac glycosides as novel cancer therapeutic agents. Mol Interv 2008; 8: 36-49
16. Foukakis T, Lundell L, Gubanski M, Lind PA. Advances in the treatment of patients with gastric adenocarcinoma. Acta Oncol 2007; 46: 277-285
17. Ribatti D, Vacca A, Rusnati M, Presta M. The discovery of basic fibroblast growth factor/fibroblast growth factor-2 and its role in haematological malignancies. Cytokine Growth Factor Rev 2007; 18: 327-334
18. Shi YH, Bingle L, Gong LH, Wang YX, Corke KP, Fang WG. Basic FGF augments hypoxia induced HIF-1-alpha expression and VEGF release in T47D breast cancer cells. Pathology 2007; 39: 396-400
19. Smith JA, Madden T, Vijjeswarapu M, Newman RA. Inhibition of export of fibroblast growth factor-2 (FGF-2) from the prostate cancer cell lines PC3 and DU145 by Anvirzel and its cardiac glycoside component, oleandrin. Biochem Pharmacol 2001; 62: 469-472
20. Cronauer MV, Hittmair A, Eder IE, Hobisch A, Culig Z, Ramoner R, Zhang J, Bartsch G, Reissigl A, Radmayr C, Thurnher M, Klocker H. Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate. Prostate 1997; 31: 223-233
21. Giehl KA, Nägele U, Volkenandt M, Berking C. Protein expression of melanocyte growth factors (bFGF, SCF) and their receptors (FGFR-1, c-kit) in nevi and melanoma. J Cutan Pathol 2007; 34: 7-14
22. Fortin D, Rom E, Sun H, Yayon A, Bansal R. Distinct fibroblast growth factor (FGF)/FGF receptor signaling pairs initiate diverse cellular responses in the oligodendrocyte lineage. J Neurosci 2005; 25: 7470-7479
23. Udayakumar TS, Klein RD, Maliner MS, Nagle RB, Bowden GT. Aberrant expression of fibroblast growth factor receptor- 1 in prostate epithelial cells allows induction of promatrilysin expression by fibroblast growth factors. Int J Cancer 2001; 91: 187-192
24. Kamura S, Matsumoto Y, Fukushi JI, Fujiwara T, Iida K, Okada Y, Iwamoto Y. Basic fibroblast growth factor in the bone microenvironment enhances cell motility and invasion of Ewing's sarcoma family of tumours by activating the FGFR1-PI3K-Rac1 pathway. Br J Cancer 2010; 103: 370-381
25. Gong J, Morishita A, Kurokohchi K, Tani J, Kato K, Miyoshi H, Inoue H, Kobayashi M, Liu S, Murota M, Muramatsu A, Izuishi K, Suzuki Y, Yoshida H, Uchida N, Deguchi K, Iwama H, Ishimaru I, Masaki T. Use of protein array to investigate receptor tyrosine kinases activated in gastric cancer. Int J Oncol 2010; 36: 101-106
26. Katoh M, Katoh M. FGF signaling network in the gastroin- testinal tract (review). Int J Oncol 2006; 29: 163-168
27. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001; 107: 241-246
28. Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005; 5: 297-309
29. Bushdid PB, Chen CL, Brantley DM, Yull F, Raghow R, Kerr LD, Barnett JV. NF-kappaB mediates FGF signal regulation of msx-1 expression. Dev Biol 2001; 237: 107-115
30. Yang Q, Huang W, Jozwik C, Lin Y, Glasman M, Caohuy H, Srivastava M, Esposito D, Gillette W, Hartley J, Pollard HB. Cardiac glycosides inhibit TNF-alpha/NF-kappaB signaling by blocking recruitment of TNF receptor-associated death domain to the TNF receptor. Proc Natl Acad Sci USA 2005; 102: 9631-9636
31. Mijatovic T, Op De Beeck A, Van Quaquebeke E, Dewelle J, Darro F, de Launoit Y, Kiss R. The cardenolide UNBS1450 is able to deactivate nuclear factor kappaB-mediated cytoprotective effects in human non-small cell lung cancer cells. Mol Cancer Ther 2006; 5: 391-399
32. Peng L, Ran YL, Hu H, Yu L, Liu Q, Zhou Z, Sun YM, Sun LC, Pan J, Sun LX, Zhao P, Yang ZH. Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway. Carcinogenesis 2009; 30: 1660-1669
33. Zheng SJ, Zheng SP, Huang FY, Jiao CL, Wu RL. Synergistic anti-tumor effect of recombinant chicken fibroblast growth factor receptor-1-mediated anti-angiogenesis and lowdose gemcitabine in a mouse colon adenocarcinoma model. World J Gastroenterol 2007; 13: 2484-2489
34. Guo J, Jie W, Kuang D, Ni J, Chen D, Ao Q, Wang G. Ischaemia/ reperfusion induced cardiac stem cell homing to the injured myocardium by stimulating stem cell factor expression via NF-kappaB pathway. Int J Exp Pathol 2009; 90: 355-364
35. Ueda A, Ishigatsubo Y, Okubo T, Yoshimura T. Transcriptional regulation of the human monocyte chemoattractant protein-1 gene. Cooperation of two NF-kappaB sites and NF-kappaB/Rel subunit specificity. J Biol Chem 1997; 272: 31092-31099
36. Jiang MM, Dai Y, Gao H, Zhang X, Wang GH, He JY, Hu QY, Zeng JZ, Zhang XK, Yao XS. Cardenolides from Antiaris toxicaria as potent selective Nur77 modulators. Chem Pharm Bull (Tokyo) 2008; 56: 1005-1008
37. Baldwin AS. Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest 2001; 107: 3-6
38. Giri DK, Aggarwal BB. Constitutive activation of NFkappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates. J Biol Chem 1998; 273: 14008-14014
39. Namba H, Saenko V, Yamashita S. Nuclear factor-kB in thyroid carcinogenesis and progression: a novel therapeutic target for advanced thyroid cancer. Arq Bras Endocrinol Metabol 2007; 51: 843-851
40. Lee JI, Burckart GJ. Nuclear factor kappa B: important transcription factor and therapeutic target. J Clin Pharmacol 1998; 38: 981-993